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Abstract
Background: Infiltrating lobular carcinoma (ILC) is the second most common type of invasive breast cancers and it has 
been reported to have some unique biologic and epidemiologic characteristics.
Methods: Clinicopathological features of 95 patients with ILC, their relapse free survival (RFS) and overall survival (OS) 
were retrospectively investigated and compared with those of 3,621 patients with infiltrating ductal carcinoma-not 
otherwise specified (IDC-NOS) between January 1984 and December 2005.
Results: ILC constitutes 2.3% of all invasive breast cancers. There were no difference between the ILC and the IDC-NOS 
groups regarding age at diagnosis, tumor size, nodal status, and treatment modalities except hormone therapy. The ILC 
group showed more estrogen receptor expression, less HER-2 expression and higher bilaterality. RFS and OS of the ILC 
patients were similar to those of the IDC. IDC-NOS metastasized more frequently to the lung and bone, whereas, ILC to 
the bone and ovary.
Conclusions: The incidence of ILC was relatively low in Korean breast cancer patients. Comparing to IDC-NOS ILC 
showed some different features such as higher estrogen receptor expression, less HER-2 expression, higher bilaterality 
and preferred metastatic sites of bone and ovary. Contralateral cancers and bone and ovary evaluation should be 
considered when monitoring ILC patients.
Background
Infiltrating lobular carcinoma (ILC) constitutes approxi-
mately 10% of invasive breast cancers, and it is the second
common histologic type of breast cancer [1]. In Korea,
the incidence of ILC is quite low, and it has been reported
as 2-4% of all breast cancers [2]. Recently, the incidence of
ILC in the West is relatively increasing, while that of infil-
trating ductal carcinoma (IDC) remains constant [1].
It has been reported that ILC has characteristics that
are different from IDC [3] such as older age onset, larger
tumor size, increased propensity for multifocality and
multicentricity, and higher risk of bilateral breast cancer.
In terms of histologic features, ILC shows better differen-
tiation, more frequent expression of estrogen receptor
(ER)-positive and progesterone receptor (PR), and less
vessel invasion. Other characteristics of ILC include
lower S-phase fraction and diploid, less HER-2, P53, and
epidermal growth factor receptor (EGF-R) expression [3].
While some reported that ILC patients showed better
prognosis, others reported poorer prognosis compared
with IDC [4]. Limitation of those studies regarding out-
comes of ILC is the relatively small sample sizes. The aim
of this study was to investigate the clinicopathological
features and outcomes of ILC, and compare them with
those of infiltrating ductal carcinoma-not otherwise
specified (IDC-NOS) in Korean patients.
Methods
We retrospectively reviewed the Severance Hospital
Breast Cancer Registry Database of 4,465 breast cancer
patients who had been treated at the Department of Sur-
gery, Yonsei University of College of Medicine, Seoul,
Korea, between January 1984 and December 2005.
Among 4,465 cases, 4,053 were invasive breast cancers:
3,621 IDC-NOS (89.3%), 95 ILC (2.3%) and 337 other
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NOS and 95 ILC were included in this study.
The patients' medical records were collected in the Sev-
erance Hospital Breast Cancer Registry Database and
reviewed to obtain data regarding general characteristics
of the patients, histopathology of primary tumors, treat-
ment modalities (surgery, chemotherapy, radiation and
hormone therapy), relapse-free survival (RFS) and overall
survival (OS). In cases of patients diagnosed with ILC, a
specialized pathologist with extensive experience in
breast pathology reviewed their pathologic slides, and in
cases of patients with IDC, we reviewed these cases
through previous pathologic reports. Histological diag-
nostic features of ILC were loosely dispersed strands of
infiltrating tumor cells, often in the form of a single file,
throughout the fibrous matrix, lacks of cohesion without
formation of tubules or papillae, and small cells with rela-
tively little nuclear pleomorphism [5]. We did not dis-
criminate between classic and variant types. Tumor
stages were determined based on the 6th American Joint
Committee on Cancer (AJCC) criteria. Histologic types
followed the World Health Organization (WHO) classifi-
cation.
All immunostainings were done with formalin-fixed
and paraffin-embedded tissue sections. Briefly, 5 μm-
thick sections were obtained with a microtome, deparaf-
finized and rehydrated. After treatment with 3% hydro-
gen peroxide solution for 10 minutes to block
endogenous peroxidases, the sections were pretreated in
10 mM citrate buffer (pH 6.0) for antigen retrieval in a
microwave oven for 20 minutes. After incubation with
primary antibodies against ER (clone SP1, 1:100; Thermo
Scientific, Fremont, CA, USA), PR (clone PgR 636, 1:50;
DAKO, Glostrup, Denmark), and HER-2 (polyclonal,
1:1500; DAKO), immunodetection was performed with
biotinylated antimouse immunoglobulin, followed by
peroxidase-labeled streptavidin using a labeled streptavi-
din biotin kit with 3,3'-diaminobenzidine chromogen as
substrate. Slides were counterstained with Harris hema-
toxylin. Hormone receptor positivity was defined as more
than 10 fmol/mg cytosol protein, or as 10% or more
nuclear stain by immunohistochemistry (IHC). IHC stain
results of HER-2 were scored by counting the number of
cells positively stained on the membrane and expressed
as a percentage of total tumor cells. HER-2 staining was
scored according to the American Society of Clinical
Oncology (ASCO)/College of American Pathologists
(CAP) guideline [6] using the following categories: 0, no
immunostaining; 1+, weak incomplete membranous
staining in any proportion of tumor cells; 2+, complete
membranous staining, either non-uniform or weak in at
least 10% of tumor cells; and 3+, uniform intense mem-
branous staining in >30% of tumor cells.
Associations between categorical variables were
assessed using a chi-square test. The RFS time was
defined as from the date of the operation to the date of
first locoregional or systemic recurrence. Locoregional
recurrence included relapses in the chest wall, operation
scar, remnant breast, axillary lymph node, supraclavicular
lymph node and internal mammary lymph node. Sys-
temic recurrences included metastases in the lung, brain,
liver, bone, ovary, kidney and other organs. The OS time
was defined as the period between the date of operation
and the date of death from any cause. Survival curves
were plotted and estimated using the Kaplan-Meier
method. Group differences in the survival time were cal-
culated by the log-rank test. The Cox proportional hazard
model was used to calculate the hazard ratio (HR) and
95% CI in the analyses of RFS and OS. A p-value less than
0.05 was considered statistically significant. SPSS for
Windows (version 15.0, SPSS Inc., Chicago, IL, U.S.A.)
was used for all statistical analyses.
Results
The mean follow-up duration was 74 ± 48.19 months in
all patients. The mean age at diagnosis was 47.43 ± 8.91
years in ILC patients and 47.69 ± 10.31 years in IDC-NOS
patients.
The clinicopathological factors are summarized in
Table 1. There was no difference in the age at diagnosis,
tumor size, nodal status and TMN stage. ILC patients
showed higher ER expression and less HER-2 expression
than IDC-NOS patients (P = 0.003 and 0.038, respec-
tively). PR expression was higher in ILC, but, there was
no statistical significance. There was a higher incidence
of bilateral cancer in the ILC group compared to the IDC-
NOS patients (P = 0.013).
Treatment modalities including operation methods
were not different between the two groups except hor-
mone therapy (Table 2). As ILC patients showed higher
ER expression rates, adjuvant hormone therapy was more
frequently given to them (P = 0.024)
The ten-year RFS rate was 61.8% for the ILC and 69.5%
for the IDC-NOS, respectively. The ten-year OS rate was
75% in ILC and 73.6% in IDC-NOS, respectively. There
was no statistical significance in the RFS (relapse-free
survival) and OS (overall survival) rates between the
groups (Figures 1 and 2) even in stage-matched analysis
(data not shown). In Table 3, recurrence patterns and fre-
quent sites of systemic recurrences are summarized. Both
groups showed similar recurrence patterns. Lung and
bone were the preferred sites of metastases in the IDC-
NOS group (lung: 37.5%, bone: 36.5%). In the ILC group,
bone was the most frequent site of metastasis followed by
ovary (bone: 72.7%, ovary: 18.2%).
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Table 1: Biological characteristics of the patients and tumors by histologic group
Histopathology
Infiltrating ductal carcinoma Infiltrating lobular carcinoma Total
Factor Number of patients
(n = 3621)
% Number of patients
(n = 95)
% Number of patients P value
Age, years 0.069
>35 3,213 88.7 90 94.7 3,303
≤35 406 11.3 5 5.3 413
T stage 0.922
T1 1,585 73.8 42 44.2 1,621
T2 1,780 49.2 49 51.6 1,825
T3 181 5 3 3.2 184
T4 72 2 1 1.1 73
N stage 0.56
N0 1,912 52.9 57 60 1,969
N1 924 25.6 22 23.2 946
N2 459 12.7 10 10.5 469
N3 316 8.8 6 6.3 322
TNM stage 0.57
Stage 1 1,066 29.5 28 29.5 1,094
Stage 2 1,703 47.2 49 51.6 1,752
Stage 3 840 23.3 18 18.9 858
Bilaterality 0.013
Unilateral 3,495 96.5 89 93.7 3,526
Bilateral 126 3.5 6 6.3 132
ER receptor 0.003
Negative 1,088 37.4 15 20.3 1,103
Positive 1,821 62.6 59 79.7 1,880
PR receptor 0.23
Negative 1,221 42.9 25 35.7 1,246
Positive 1,625 57.1 45 64.3 1,670
HER-2 0.038
Negative 1,373 70.8 46 83.6 1,419
Positive 567 29.2 9 16.4 576
ER = estrogen receptor; PR = progesterone receptor; HER-2 = human epidermal growth factor receptor-2.
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ILC is the second most common type of invasive breast
cancers. According to the database of the National Can-
cer Institute from the period of 1992 up to 2001, 70% of
all breast cancers were IDC, 8% were ILC, 7% were duc-
tal/lobular type and the remaining 9% were various rare
entities [1]. In American and European studies, the por-
tion of ILC was reported to be about 10~14% [7]. How-
ever, the portion of ILC in Korea was lower than that of
outside the country, and it was reported to be 2~4% [2,8].
In this analysis, ILC accounted for 2.3%, a level similar to
those found in other Korean studies. Taken together, the
Table 2: Local and systemic adjuvant therapies by histologic type
Histopathology
Infiltrating ductal carcinoma Infiltrating lobular carcinoma Total
Number of patients % Number of patients % Number of patients P value
Local Tx 0.297
BCS 735 20.3 15 16 750
Mastectomy 2,880 79.7 79 84 2,959
Radiation Tx 0.405
None 2,188 63.8 53 59.6 2,241
Radiation Tx 1,239 36.2 36 40.4 1,275
Chemotherapy 0.898
None 988 28 26 27.4 1,014
Chemotherapy 2,545 72 69 72.6 2,614
Hormone Tx 0.024
None 1,553 45.1 31 33.3 1,584
Hormone Tx 1,889 54.9 62 66.7 1,951
BCS = breast conserving surgery; Tx = therapy.
Figure 1 Overall survival. Figure 2 Relapse-free survival.
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Western countries.
Comparing to patients with IDCs, patients with ILC are
older than those with IDC [7,9]. However, there was no
difference in the age at diagnosis between the two groups
in our analysis. Low incidence of ILC and no difference in
the age at diagnosis could be partly explained by different
genetic or environmental factors of Korean breast cancer
patients compared to those of Western countries [10] and
the epidemiologic characteristics of Korean breast can-
cers [2]. The incidence of breast cancer in European and
American women increases as they get older. In Korean
women, however, the incidence of age distribution
reaches the peak in their 40's, and then it declines after-
wards. The most prevalent age for breast cancer in Korea
is 10 years younger than that in Western countries [8].
Some studies reported that tumor size was slightly
larger in the ILC group [9]. The lack of desmoplastic reac-
tion may make the lesion impalpable and invisible, both
clinically and mammographically, which could partly
explain why lobular carcinomas were larger at diagnosis
than IDCs [11]. However, no difference in tumor size was
observed between the two groups in this study. Because
of the high incidence of young breast cancer patients, the
use of ultrasonography is very popular, which might in
some part contribute to early detection of ILC as well as
IDC in Korea.
Axillary lymph node involvement was not different
between the two groups in our study. MacGrogan et al.
[12] reported that the uniform appearance of bland
tumor cells that lack cellular atypia and often have a low
mitotic rate make it more difficult to correctly detect lob-
ular cancer cells in metastatic lymph nodes. That is why
nodal metastases are more often undetected in patients
with ILC, and false-negative results are more frequently
reported compared with ductal carcinomas [12]. There-
fore, pathologists should be informed of the ILC case
before interpreting the frozen slides of sentinel lymph
nodes during surgery.
In agreement with other previous studies [13,14],
higher rate of ER expression and lower incidence of HER2
expression were demonstrated in this study. ILC is more
often found to be multifocal, multicenteric and bilateral
than IDCs. Bilateral involvement has been reported to be
20~29% in lobular carcinoma [15,16]. We also observed
that bilateral involvement was more common in ILC
(6.3%) compared to that in IDC-NOS (3.5%) (P = 0.013).
Several studies reported that ILC was less often treated
with breast conserving surgery than IDC [7,9]. This is
attributed to the difficulty in defining tumor margins
Table 3: Recurrence patterns and distant sites of the first recurrence by histopathologic type
Histopathology
Infiltrating ductal carcinoma Infiltrating lobular carcinoma Total
Number of patients % Number of patients % Number of patients P value
Pattern of recurrence 0.097
Locoregional recurrence 123 14.4 3 18.8 123
Systemic recurrence 480 56.1 12 75.0 492
Locoreginal recurrence 
and systemic recurrence
252 29.5 1 6.3 253
Site of systemic recurrence
Lung 264 37.5 1 9.1 254
Brain 50 7.1 0 0 49
Liver 105 14.9 0 0 105
Bone 257 36.5 8 72.7 261
Ovary 1 0.1 2 18.2 2
Pericardium, pleura 10 1.4 0 0 8
Contalateral SCN 4 0.6 0 0 7
Othera 13 1.8 0 0 19
Othera contains opposite breast (2), contralateral axilla (1), mediastinum (1), carcinomatosis (4), adrenal gland (2), multiple lymph node (1), 
neck node (2). SCN = supraclavicular lymph node.
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ity of obtaining positive surgical margins due to tumor
characteristics of multifocality or multicentricity [3]. His-
tologically ILC presents a loosely dispersed single cell
pattern of growth throughout the stroma, lacks of desmo-
plastic reactions, and is often associated with lobular car-
cinoma in-situ and inflammatory cells around ducts may
mimic the targetoid pattern of ILC [5,17]. These can pres-
ent notable diagnostic problems, especially in frozen sec-
tion or in core needle biopsy specimens. In our study, less
ILC patients underwent breast conserving surgery than
IDC-NOS patients did, but there was no statistical differ-
ence. Some researchers reported that breast conserving
surgery in ILC patients is not associated with increased
local relapse rates at 5 years when compared with mastec-
tomy. Therefore, ILC can be treated with breast conserv-
ing surgery when clear margin can be achieved [7,18]. In
terms of adjuvant therapy, both radiation therapy and
chemotherapy were performed irrespective of histologic
type. However, patients with ILC were more likely to
undergo anti-estrogen therapy.
In terms of prognosis, some studies reported that the
prognosis of ILC patients was similar to that of patients
with IDC, and histologic type was not a factor affecting
the prognosis [7,11]. Others reported that early prognosis
for ILC was better than that for IDC, while late prognosis
for ILC was worse [3]. In this analysis, RFS and OS were
similar between the two groups.
The locoregional or systemic recurrence pattern of ILC
was similar to that of IDC-NOS in our study. Still, the dis-
tant metastatic sites of ILC differed from those of IDC-
NOS. It was observed that ILC is less likely to affect the
lungs, pleura, and CNS than IDC-NOS does. By contrast,
bone, peritoneum, ovary, meniges, and the gastrointesti-
nal system were much more likely to be affected by ILC
[3,19,20]. As in other reports, the current study demon-
strated that bone and ovary were the preferred sites of
metastasis but lung and liver were rarely affected by ILC.
Difference in favoring metastatic sites by histologic types
might be attributable to the microenvironments of the
ovary or peritoneum which might provide growth and
survival factors that favor ILC cells over IDC cells [21,22].
Some reported that loss of expression of the cell-cell
adhesion molecule E-cadherin in ILC may decrease adhe-
siveness of cells and facilitate this type of infiltration [23].
Alternatively, cell size or shape with physical properties
might favor certain microanatomical areas and that is
more conductive to stopping or trapping these types of
cells [19].
The limitation of our study was the HER-2 results. We
defined HER-2 overexpression as 2+ or 3+ cases by HER-
2 immunohistochemical testing in our study. During the
periods under study approximately half of the study
cohorts did not perform HER-2 immunohistochemical
testing and furthermore, FISH was not a routine test for
patients with 2+ results in our institution. This definition
would overestimate the cases with HER-2 overexpression.
However, this study is not confirmative but exploratory
by retrospective review of data. Therefore, we concen-
trated on the sensitivity of HER-2 immunohistochemical
testing. HER-2 immunohistochemical testing compared
with FISH showed high sensitivity, negative predictive
value, and overall accuracy when HER-2 overexpression
was defined as 2+ or 3+ immunohistochemical results
[24,25]. Overall HER-2 overexpression rates of our study
cohorts were 28.9% (576/1995), which did not signifi-
cantly different from previous report [26].
In summary, low incidence of ILC in the Korean breast
cancer population might be associated with younger age
onset epidemiologic characteristics of the Korean popu-
lation. ILC has some different characteristics from IDC
such as more frequent estrogen receptor expression, less
frequent HER-2 expression, high incidence of bilaterality
and bone and ovary preference of metastases. Based on
the histologic and biologic characteristics, researchers
should be focused on the occurrence of contralateral
breast cancers and preferred sites of metastasis during
follow up. In Korea, the incidence of ILC is relatively
lower than that in Western. However, increase in life
expectancy or patients with breast carcinoma and change
to westernized life style in Korea might lead to increase
the incidence of ILC. Therefore, it should be necessary to
understand clinicopathological features or tumor biology
of ILC and to provide appropriate diagnostic or therapeu-
tic guidelines for ILC.
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